Tải bản đầy đủ
CHƯƠNG 5. KẾT LUẬN VÀ ĐỀ NGHỊ

CHƯƠNG 5. KẾT LUẬN VÀ ĐỀ NGHỊ

Tải bản đầy đủ

TÀI LIỆU THAM KHẢO
Tài liệu tiếng Việt

1. Bộ môn dược liệu (2012), Giáo trình phương pháp nghiên cứu dược liệu, Đại
học Y Dược Tp.Hồ Chí Minh, tr.72-84 .

2. Châu Ngọc Hoa (2012), Bệnh học nội khoa, NXB Y Học, TP. HCM, tr.68-80.
3. Mai Phương Mai (2012), Dược Lý Học, NXB Y Học, Hà Nội, tr.47-53.
4. Phạm Khánh Phong Lan (2007), Các phương pháp quang phổ xác định cấu trúc
hợp chất hữu cơ 2, Đại học Y Dược TPHCM, tr.9-60.

5. Võ Thị Bạch Huệ, Vĩnh Định (2008), Hóa phân tích 2, Nhà xuất bản Y học,
tr.106-119.
Tài liệu nước ngoài
Sách

6. G.K. McEvoy (2011), AHFS Drug Information Essentials, American Society of
Health-System Pharmacists, Inc., Maryland.

7. R. Ramanathan (2009), Mass Spectrometry in Drug Metabolism and
Pharmacokinetics, A Jonh Wiley & Sons, INC., p.12.

8. S. Budavari, M.J. O’Neil, A. Smith, P.E. Heckelman (1989), The Merck index,
Merck & CO., MỸ
Tạp chí

9. Al. Williamson (1851), “Ueber die Theorie der Aetherbildung”, A. Ann. Chem.
Pharm., 77(1), 37-49.

10.

Alexander W. Williamson, Ph.D. F.C.S (1852), “XXII.-On etherification”, J.

Chem. Soc., 4(3), 229-239.

11.

M.C. Allely, B.J. Alps (1990), “Prevention of myocardial enzyme release by

Ranolazin in a primate model of ischaemia with reperfusion”, Br J Pharmacol.,
99(1), 5–6.

12.

B. Bhandari, L. Subramanian (2007), “Ranolazin, a partial fatty acid

oxidation inhibitor, its potential benefit in angina and other cardiovascular
disorders”, Recent Pat Cardiovasc Drug Discov., 2(1), 35-39.

13.

B.M. Reddly, H.S. Weintraub, A.Z. Schwartzbard (2010), “Ranolazin A New

Approach to Treating an Old Problem”, Texas Heart Institute Journal, 37(6),
641-647.
14. B.R. Kim et al (2012), “tert-Butoxide-Assisted Amidation of Esters under Green
Conditions”, Synthesis 2012, 44(1), 42-45

15.

C.E.R. Agiai, T.K. Gizur, K.F. Harsan Yi, F.U. Trischler, S.A.A. Dermether,

A.L. Csehi, E.S. Vijda and G.A. Szab-komi si (1991), “Process For The
Preperation Of Piperazin Derivatives”, Eur. Pat, EP 0483932 A1.

16.

B.R.

Chaitman, C.J.

Pepine, J.O.

Parker, J.

Skopal, G.

Chumakova,

J. Kuch, W. Wang, SL. Skettino, A.A. Wolff (2004), “Effects of Ranolazin with
atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in
patients with severe chronic angina: a randomized controlled trial”, JAMA,
291(3), 309-316.

17.

B.R. Chaitman (2004), “Efficacy and safety of a metabolic modulator drug in

chronic stable angina: review of evidence from clinical trials”, J. Cardiovasc
Pharmacol Ther., 9(1), 47–64.

18.

D. Chunyun, Z. Yi Hong, El.H. Aziza et al (2014), “Ranolazin inhibition of

hERG potassium channels: Drug–pore 3 interactions and reduced potency
against inactivation mutants”, J Mol Cell Cardiol.,74(1), 220-230.

19. D.N. Kommi, D. Kumar and A.K. Chakraborti (2013), “ “All water chemistry”
for a concise total synthesis of the novel class anti-anginal drug (RS), (R), and
(S)-ranolazine”, Green Chem., 15(1), 756–767.

20.

K. Fox, M.A. Garcia, D. Ardissino et al (2006), “Guidelines on the

management of stable angina pectoris: executive summary: The Task Force on
the Management of Stable Angina Pectoris of the European Society of
Cardiology”, Eur Heart J., 27(11), 1341–1381.

21.

G.A. Youngdale, G.W. Duncan, D.E. Emmert, D. Lednicer (1966),

“Synthesis

and

Antifertility

Activity

of

5-(Phenoxymethpl)-2-

oxazolidinethiones”, J. Med. Chem., 9(1), 155-157.

22.

H. Hyosook, M.A. Joseph, L.H. Sharon, Z.S. Boris et al (2009), “Ranolazin

as an Adjunct to Cardioplegia: A Potential New Therapeutic Application”, J
Cardiovasc Pharmacol Ther., 14(2), 125-133.

23.

K. Audouze, E.S Nielsen and D. Pethers (2004), “New Series of Morpholine

and 1,4-Oxazepane Derivatives as Dopamine D4 Receptor Ligands: Synthesis
and 3D-QSAR Model”, Journal of Medicinal Chemistry, 47(12), 3089-3104.

24.

Kluge

et

al

(1986),

“Cardioselect

Ive

Aryloxy-

And

Arylthio

Hydroxypropylene-Piperazinyl Acetanilides Which Affect Calcium Entry”, U.S
Pat. No. 4,567,264.

25.

L.R. Madivada, R.R. Anumala, G.Gilla, M.Kagga and R. Bandichhor (2012),

“An Efficient Synthesis of 1-(2-methoxyphenoxy)-2,3-epoxypropan: Key
Intermediate of β-Adrenoblockers”, Org. Process Res. Dev., 16(10), 1660-1664.

26.

M. Aldakkak, D.F. Stowel and A.K.S Camara (2013), “Safety and Efficacy of

Ranolazin for the Treatment of Chronic Angina Pectoris”, Clin Med Insight
Ther., 2013(5), 1-14.

27.

P. Lamendola et al (2013), “Effect of Ranolazin on arterial endothelial

function in patients with type 2 diabetes mellitus”, Atherosclerosis, 226(1), 157160.

28.

P.B Deshpande, A.D. Chauhan (2006), “Crystalline and amorphous form of

Ranolazin and process for manufacturing them”, PCT Int Pat, WO 2006008753
A1.

29.

R.M. Anders, K. Rasmus and A. Thorleif (2005), “Chemo-enzymatic

synthesis of both enantiomers of the anti-anginal drug Ranolazin”, Biocatalysis
and Biotransformation, 23(1), 45-51.

30.

V.L. Roger, A.S. Go, D.M. Lloyd-Jones et al. (2012), “Executive summary:

heart disease and stroke statistics-2012 update: a report from the American Heart
Association”, Circulation, 125(1), 188-97.

31.

S. Aalla, G. Gilla, R.R. Anumula et al (2012), “Improved Process For

Ranolazin: An Antianginal Agent”, Org. Process Res. Dev., 16(5), 748-754.

32.

T. Ohshima, Y. Hayashi, K. Agura, Y. Fujii, A. Yoshiyama and K. Mashima

(2012), “Sodium methoxide: a simple but highly efficient catalyst for the direct
amidation of ester”, Chemical Communication, 44(1), 5434-5436.

33.

A.D. Timmis, B.R. Chaitman and M. Crager (2006), “Effects of Ranolazin

on exercise tolerance and HbA1c in patients with chronic angina and diabetes”,
Eur Heart J, 27( 1), 42–48.

34.

Yao, Zhangyu, Gong, Shubo, Guan, Teng, Li, Yunman, Wu, Xiaoming, Sun,

Hongbin (2009), “Synthesis of Ranolazin Metabolites and Their Antimyocardial Ischemia Activities”, Chemical and Pharmaceutical Bulletin,
57(11), 1218-1222.

PHỤ LỤC

hụ lục 4.1 Phổ IR của 1-2(methoxyphenoxy)-2,3-epoxypropan (RO-1)

hụ lục 4.2 Phổ 1H-NMR của 1-(2-methoxyphenoxy)-2,3-epoxypropan (RO-1)

hụ lục 4.3 Phổ 1H-NMR mở rộng của 1-(2-methoxyphenoxy)-2,3-epoxypropan (RO-1)

hụ lục 4.4 Phổ 1H-NMR của 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazin (RO-2)

hụ lục 4.5 Phổ 1H-NMR mở rộng của 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]piperazin (RO-2)